Cagrilintide
Also known as AM833, Long-acting amylin analog
An investigational long-acting amylin analog studied for appetite regulation, satiety, obesity, and combination use with semaglutide in CagriSema.
Overview
Cagrilintide is a long-acting analog of amylin, a pancreatic hormone involved in satiety and post-meal glucose regulation. It is best known publicly as the amylin component of CagriSema.
The Science
Amylin signaling complements incretin signaling but is not the same pathway.
- Satiety signaling - amylin contributes to meal termination and fullness.
- Gastric and glucose context - amylin biology intersects with postprandial regulation.
- Combination research - cagrilintide is studied with semaglutide to layer amylin and GLP-1 effects.
Evidence Snapshot
Cagrilintide is investigational. The strongest public evidence is in controlled clinical trials, especially in combination with semaglutide, not arbitrary vendor blends.
References
- [1]Frias JP et al. Co-administered cagrilintide 2.4 mg with semaglutide 2.4 mg in type 2 diabetes(2023) · doi:10.1016/S0140-6736(23)01163-7
- [2]Garvey WT et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity(2025) · doi:10.1056/NEJMoa2502081
Related
More in Metabolic
Adipotide
Research compoundMetabolic
An experimental peptidomimetic studied preclinically for targeting adipose vasculature through prohibitin-related mechanisms, with major translational and safety uncertainty.
AICAR
Research compoundMetabolic
Not a peptideNucleotide analog
A nucleotide analog and AMPK-pathway research tool studied in cellular energy sensing, exercise-mimetic biology, cardiometabolic research, and anti-doping contexts.
AOD-9604
Research compoundMetabolic
A synthetic fragment of growth hormone designed to isolate GH's fat-mobilizing effects without its growth-promoting or blood-sugar-altering activity — a tool researchers and self-experimenters study for body composition and joint health.